Markets:

Overview

News

Currencies

International

Treasuries

PolyPid Ltd. - Ordinary Shares (NQ:PYPD)

6.500 +0.190 (+3.01%)

Delayed Quote Updated: 2:34 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PolyPid Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >

What PolyPid (PYPD) Said on Its Q3 Earnings Call ↗

Today 10:15 EST

PolyPid (NASDAQ:PYPD) is approaching a Nov. 28 U.S. regulatory decision on D-PLEX100, its experimental product for preventing surgical site infections in patients undergoing colorectal surgery, while...

Via MarketBeat

Topics Earnings

PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program ↗

October 29, 2026

PolyPid (NASDAQ:PYPD) outlined plans to expand its commercial and development strategy through 2030 at an investor day, as the company approaches a November 28, 2026, FDA action date for its D-PLEX100...

Via MarketBeat

PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data ↗

October 04, 2026

PolyPid (NASDAQ:PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief...

Via MarketBeat

Topics Bonds

PolyPid (PYPD) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

FDA accepts D-PLEX100 application with Priority Review, setting November approval target.

Via The Motley Fool

Topics Earnings

PolyPid Ltd (NASDAQ:PYPD) Reports Q4 2025 Results, Focus on D-PLEX₁₀₀ Partnership and Regulatory Progress ↗

February 11, 2026

Via Chartmill

PolyPid Q2 Earnings Call Highlights ↗

August 12, 2026

PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA’s acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering...

Via MarketBeat

Topics Earnings

PolyPid (PYPD) Q1 2026 Earnings Transcript ↗

May 13, 2026

PolyPid (PYPD) Q1 2026 Earnings Transcript

Via The Motley Fool

PolyPid Q1 Earnings Call Highlights ↗

May 13, 2026

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate...

Via MarketBeat

Topics Earnings

PolyPid (PYPD) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

PolyPid (PYPD) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

A Look Ahead: PolyPid's Earnings Forecast ↗

May 13, 2025

Via Benzinga

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA

December 03, 2025

Jerusalem, Israel – December 3, 2025 – PolyPid Ltd. (NASDAQ: PYPD) witnessed a significant surge in its stock price today, gaining 3.4% following the announcement of supportive feedback from the U.S....

Via MarketMinute

An Overlooked Crisis in Hospitals Could Be Pharma’s Next Great Opportunity

October 13, 2025

Via AB Newswire

These stocks are moving in today's pre-market session ↗

August 18, 2025

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 18, 2025

Via Benzinga

Cisco To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 14, 2025

Via Benzinga

POLYPID LTD (NASDAQ:PYPD) Reports Q2 2025 Results with Mixed Market Reaction Despite Positive Phase 3 D-PLEX₁₀₀ Data ↗

August 13, 2025

PolyPid reports Q2 2025 results with positive Phase 3 data for D-PLEX₁₀₀, but EPS miss and no revenue. Stock dips slightly pre-market.

Via Chartmill

PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market

July 15, 2025

Via AB Newswire

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval

June 18, 2025

Surgical infection prevention breakthrough demonstrates 58% infection reduction as company secures funding through regulatory approval (NASDAQ:PYPD)*

Via News Direct

These stocks have an unusual volume in today's session ↗

June 10, 2025

Volume analysis on 2025-06-10: stocks with an unusual volume in today's session.

Via Chartmill

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial ↗

June 09, 2025

PolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or death after colorectal surgery vs. standard care.

Via Benzinga

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

June 09, 2025

Via Benzinga

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 05, 2025

Via Benzinga

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

March 18, 2025

Via ACCESS Newswire

PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025

February 27, 2025

Via ACCESS Newswire

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday ↗

December 26, 2024

Via Benzinga

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

PolyPid Ltd. - Ordinary Shares (NQ:PYPD)

All News about PolyPid Ltd. - Ordinary Shares

Starting at /week.